Formulation, Development, and in-vitro Evaluation of Escitalopram Fast Dissolving Tablets
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Escitalopram, a selective serotonin reuptake inhibitor (SSRI), acts by increasing the serotonin level in the brain and is used widely for the management of depression and anxiety disorders. However, the poor dissolution rate of escitalopram due to less water solubility is a consequential problem confronting the pharmaceutical industry in developing pharmaceutical dosage forms for oral delivery systems.
OBJECTIVE: The present work aims to deliver a novel formulation for improving the dissolution profile and, thus, the bioavailability of escitalopram.
METHODS: Fast Dissolving Tablets (FDT) are expected to enable quick drug release, which will improve the drug's dissolving profile, allowing for the initial increase in plasma concentration mandatory in an acute depression attack. The use of co-processed excipients in tablets has been shown to increase the compressibility and disintegration properties of the tablets, resulting in improved in-vitro drug release and bioavailability. As co-processed excipients, a mixture of banana powder (a natural super disintegrant with nutritional value) and microcrystalline cellulose (a highly compressible substance with good wicking and absorption capacity) was used.
RESULTS: The tablets were made using a response surface, randomised central composite design, and a direct compression technique. The manufactured tablets were found to be released more than 95% of the drug within 10 minutes and showed an improved drug release profile than the available marketed formulation.
CONCLUSION: After confirming in-vivo potential, the fast release formulation exhibited impressive in-vitro findings and may prove to be a boon in treating acute depression attacks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Central nervous system agents in medicinal chemistry - 22(2022), 3 vom: 24., Seite 198-213 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bhatia, Vishal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4O4S742ANY |
|---|
| Anmerkungen: |
Date Completed 19.12.2022 Date Revised 22.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871524922666220624113719 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342696122 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342696122 | ||
| 003 | DE-627 | ||
| 005 | 20231226014720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871524922666220624113719 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1142.xml |
| 035 | |a (DE-627)NLM342696122 | ||
| 035 | |a (NLM)35748551 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bhatia, Vishal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Formulation, Development, and in-vitro Evaluation of Escitalopram Fast Dissolving Tablets |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.12.2022 | ||
| 500 | |a Date Revised 22.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Escitalopram, a selective serotonin reuptake inhibitor (SSRI), acts by increasing the serotonin level in the brain and is used widely for the management of depression and anxiety disorders. However, the poor dissolution rate of escitalopram due to less water solubility is a consequential problem confronting the pharmaceutical industry in developing pharmaceutical dosage forms for oral delivery systems | ||
| 520 | |a OBJECTIVE: The present work aims to deliver a novel formulation for improving the dissolution profile and, thus, the bioavailability of escitalopram | ||
| 520 | |a METHODS: Fast Dissolving Tablets (FDT) are expected to enable quick drug release, which will improve the drug's dissolving profile, allowing for the initial increase in plasma concentration mandatory in an acute depression attack. The use of co-processed excipients in tablets has been shown to increase the compressibility and disintegration properties of the tablets, resulting in improved in-vitro drug release and bioavailability. As co-processed excipients, a mixture of banana powder (a natural super disintegrant with nutritional value) and microcrystalline cellulose (a highly compressible substance with good wicking and absorption capacity) was used | ||
| 520 | |a RESULTS: The tablets were made using a response surface, randomised central composite design, and a direct compression technique. The manufactured tablets were found to be released more than 95% of the drug within 10 minutes and showed an improved drug release profile than the available marketed formulation | ||
| 520 | |a CONCLUSION: After confirming in-vivo potential, the fast release formulation exhibited impressive in-vitro findings and may prove to be a boon in treating acute depression attacks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Co-processed excipients | |
| 650 | 4 | |a bioavailability | |
| 650 | 4 | |a depression | |
| 650 | 4 | |a escitalopram banana powder | |
| 650 | 4 | |a fast-dissolving tablets | |
| 650 | 4 | |a microcrystalline cellulose | |
| 650 | 7 | |a Excipients |2 NLM | |
| 650 | 7 | |a Escitalopram |2 NLM | |
| 650 | 7 | |a 4O4S742ANY |2 NLM | |
| 650 | 7 | |a Tablets |2 NLM | |
| 700 | 1 | |a Dhingra, Ashwani K |e verfasserin |4 aut | |
| 700 | 1 | |a Dass, Rameshwar |e verfasserin |4 aut | |
| 700 | 1 | |a Chopra, Bhawna |e verfasserin |4 aut | |
| 700 | 1 | |a Guarve, Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Central nervous system agents in medicinal chemistry |d 2008 |g 22(2022), 3 vom: 24., Seite 198-213 |w (DE-627)NLM185149960 |x 1875-6166 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:3 |g day:24 |g pages:198-213 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871524922666220624113719 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 3 |b 24 |h 198-213 | ||